AR114972A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- AR114972A1 AR114972A1 ARP190101711A ARP190101711A AR114972A1 AR 114972 A1 AR114972 A1 AR 114972A1 AR P190101711 A ARP190101711 A AR P190101711A AR P190101711 A ARP190101711 A AR P190101711A AR 114972 A1 AR114972 A1 AR 114972A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- hydroxy
- phenyl
- groups
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula (1), o una sal farmacéutica del mismo. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, para su uso en un método de terapia, en donde: R¹, R², R³ y R⁴ se seleccionan independientemente entre: (i) H; (ii) alquilo C₁₋₃, opcionalmente sustituido con: hidroxi, alcoxi C₁₋₂, opcionalmente sustituido con uno o más grupos flúor, NH₂, fenilo, heteroarilo C₅₋₆, alquilcarbamoílo C₁₋₄, acilamido, o uno o más grupos flúor; (iii) alcoxi C₁₋₃, opcionalmente sustituido con cicloalquilo C₃₋₆ o con uno o más grupos flúor; (iv) cicloalquilo C₃₋₆; (v) halo; (vi) CORC, donde RC se selecciona entre NRN¹RN², donde RN¹ y RN² se seleccionan independientemente entre H y metilo; (vii) ciano, NH₂ o NO₂; y (viii) fenilo o heteroarilo C₅₋₆, opcionalmente sustituido con metilo, ciano, hidroxi o metoxi; Ar es un grupo fenilo, naftilo o heteroarilo C₅₋₁₀, estando estos grupos opcionalmente sustituidos con uno o más grupos seleccionados entre: (i) alquilo C₁₋₄, opcionalmente sustituido con hidroxi, alcoxi C₁₋₂, NH₂, alquilcarbamoílo C₁₋₄, o con uno o más grupos flúor; (ii) cicloalquilo C₃₋₆; (iii) hidroxi; ciano; NRN³RN⁴, donde RN³ y RN⁴ se seleccionan independientemente entre H y metilo; o acilamido; (iv) halo; (v) alcoxi C₁₋₃, opcionalmente sustituido con hidroxi, C(O)NH₂, cicloalquilo C₃₋₆, fenilo, heteroarilo C₅₋₆, o con uno o más grupos flúor; (vi) fenoxi, opcionalmente sustituido con flúor; (vii) fenilo o heteroarilo C₅₋₆; (viii) SF₅ o SO₂CH₃; (ix) -(CH₂)ₙ-Y-, donde Y es O ó CH₂, y n es 2 ó 3; o (x) alquil C₁₋₄ éster.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1810092.5A GB201810092D0 (en) | 2018-06-20 | 2018-06-20 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR114972A1 true AR114972A1 (es) | 2020-11-11 |
Family
ID=63042663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190101711A AR114972A1 (es) | 2018-06-20 | 2019-06-21 | Compuestos |
Country Status (39)
Country | Link |
---|---|
US (2) | US20200039945A1 (es) |
EP (2) | EP3810602B1 (es) |
JP (1) | JP2021529738A (es) |
KR (1) | KR20210022655A (es) |
CN (1) | CN112334466A (es) |
AR (1) | AR114972A1 (es) |
AU (1) | AU2019289888A1 (es) |
BR (1) | BR112020025869A2 (es) |
CA (1) | CA3101238A1 (es) |
CL (1) | CL2020003219A1 (es) |
CO (1) | CO2020014586A2 (es) |
CR (1) | CR20210032A (es) |
CU (1) | CU20200096A7 (es) |
DK (1) | DK3810602T3 (es) |
DO (1) | DOP2020000249A (es) |
EA (1) | EA202092451A1 (es) |
EC (1) | ECSP20075270A (es) |
ES (1) | ES2967983T3 (es) |
FI (1) | FI3810602T3 (es) |
GB (1) | GB201810092D0 (es) |
GE (1) | GEP20227403B (es) |
HR (1) | HRP20231467T1 (es) |
HU (1) | HUE064744T2 (es) |
IL (1) | IL279554A (es) |
LT (1) | LT3810602T (es) |
MA (1) | MA52948B1 (es) |
MD (1) | MD3810602T2 (es) |
MX (1) | MX2020012723A (es) |
NI (1) | NI202000092A (es) |
PE (1) | PE20210181A1 (es) |
PH (1) | PH12020500673A1 (es) |
PL (1) | PL3810602T3 (es) |
PT (1) | PT3810602T (es) |
RS (1) | RS64932B1 (es) |
SG (1) | SG11202010450VA (es) |
SI (1) | SI3810602T1 (es) |
TW (1) | TWI826471B (es) |
UY (1) | UY38270A (es) |
WO (1) | WO2019243491A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3471271A1 (en) | 2017-10-16 | 2019-04-17 | Acoustical Beauty | Improved convolutions of digital signals using a bit requirement optimization of a target digital signal |
MX2021016085A (es) * | 2019-06-18 | 2022-04-20 | Pfizer | Derivados de benzisoxazol sulfonamida. |
AU2020295006B2 (en) * | 2019-06-19 | 2023-11-09 | Ctxt Pty Ltd | Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives |
EP3999490A4 (en) | 2019-07-12 | 2023-03-08 | Canopy Growth Corporation | CANNABINOID DERIVATIVES |
MX2023000735A (es) | 2020-07-15 | 2023-02-13 | Pfizer | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. |
KR20240012434A (ko) * | 2021-05-21 | 2024-01-29 | 오리진 온콜로지 리미티드 | Kat6a 저해제로서의 융합된 이속사졸릴 화합물 |
EP4368620A1 (en) * | 2021-07-05 | 2024-05-15 | Hangzhou Innogate Pharma Co., Ltd. | Compound serving as kat6 inhibitor |
EP4385989A1 (en) | 2021-08-10 | 2024-06-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
KR20240109267A (ko) * | 2021-11-16 | 2024-07-10 | 인실리코 메디신 아이피 리미티드 | 리신 아세틸트랜스퍼라제 6a (kat6a) 억제제 및 그의 용도 |
WO2023114710A1 (en) * | 2021-12-13 | 2023-06-22 | Aurigene Oncology Limited | Fused benzoisoxazolyl compounds as kat6a inhibitors |
TW202400593A (zh) | 2022-03-28 | 2024-01-01 | 美商艾索司特瑞克斯公司 | Myst家族離胺酸乙醯轉移酶之抑制劑 |
WO2023245150A1 (en) * | 2022-06-16 | 2023-12-21 | Prelude Therapeutics Incorporated | Kat6 targeting compounds with ubiquitin ligase binding moiety |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
IL125686A (en) | 1996-02-13 | 2002-11-10 | Zeneca Ltd | Quinazoline derivatives, processes for their preparation, pharmaceutical preparations containing them and their use in the manufacture of a drug with an anti-angiogenic effect and / or an effect of reducing vascular permeability |
WO1997032856A1 (en) | 1996-03-05 | 1997-09-12 | Zeneca Limited | 4-anilinoquinazoline derivatives |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
NZ337750A (en) | 1997-02-12 | 2001-08-31 | Univ Michigan | Protein markers for lung cancer and use thereof |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CZ303692B6 (cs) | 1999-02-10 | 2013-03-13 | Astrazeneca Ab | Chinazolinové deriváty jako inhibitory angiogeneze |
IL149034A0 (en) | 1999-11-05 | 2002-11-10 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
MXPA02008021A (es) | 2000-02-15 | 2004-04-05 | Sugen Inc | Indolinonas sustituidas con pirroles inhibidoras de proteinquinasas. |
IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
RU2003103603A (ru) | 2000-07-07 | 2004-08-20 | Энджиоджен Фармасьютикалз Лимитед (Gb) | Производные колхинола в качестве ингибиторов ангиогенеза |
WO2002004434A1 (en) | 2000-07-07 | 2002-01-17 | Angiogene Pharmaceuticals Limited | Colchinol derivatives as vascular damaging agents |
WO2010079443A1 (en) * | 2009-01-12 | 2010-07-15 | Pfizer Limited | Sulfonamide derivatives |
US9493429B2 (en) * | 2013-03-15 | 2016-11-15 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
MX2016013913A (es) * | 2014-04-23 | 2016-11-15 | Mitsubishi Tanabe Pharma Corp | Compuesto heterociclico biciclico o triciclico novedoso. |
GB201510019D0 (en) | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2018102419A1 (en) * | 2016-11-29 | 2018-06-07 | Epizyme, Inc. | Compounds containing a sulfonic group as kat inhibitors |
MX2021016085A (es) * | 2019-06-18 | 2022-04-20 | Pfizer | Derivados de benzisoxazol sulfonamida. |
-
2018
- 2018-06-20 GB GBGB1810092.5A patent/GB201810092D0/en not_active Ceased
-
2019
- 2019-06-20 GE GEAP201915535A patent/GEP20227403B/en unknown
- 2019-06-20 BR BR112020025869-5A patent/BR112020025869A2/pt unknown
- 2019-06-20 PT PT197347222T patent/PT3810602T/pt unknown
- 2019-06-20 EP EP19734722.2A patent/EP3810602B1/en active Active
- 2019-06-20 KR KR1020217001354A patent/KR20210022655A/ko unknown
- 2019-06-20 RS RS20231178A patent/RS64932B1/sr unknown
- 2019-06-20 EA EA202092451A patent/EA202092451A1/ru unknown
- 2019-06-20 DK DK19734722.2T patent/DK3810602T3/da active
- 2019-06-20 CN CN201980041013.4A patent/CN112334466A/zh active Pending
- 2019-06-20 HU HUE19734722A patent/HUE064744T2/hu unknown
- 2019-06-20 AU AU2019289888A patent/AU2019289888A1/en active Pending
- 2019-06-20 CA CA3101238A patent/CA3101238A1/en active Pending
- 2019-06-20 TW TW108121417A patent/TWI826471B/zh active
- 2019-06-20 SI SI201930674T patent/SI3810602T1/sl unknown
- 2019-06-20 PE PE2020001917A patent/PE20210181A1/es unknown
- 2019-06-20 FI FIEP19734722.2T patent/FI3810602T3/fi active
- 2019-06-20 PL PL19734722.2T patent/PL3810602T3/pl unknown
- 2019-06-20 MX MX2020012723A patent/MX2020012723A/es unknown
- 2019-06-20 HR HRP20231467TT patent/HRP20231467T1/hr unknown
- 2019-06-20 UY UY0001038270A patent/UY38270A/es unknown
- 2019-06-20 EP EP23202715.1A patent/EP4335439A3/en active Pending
- 2019-06-20 WO PCT/EP2019/066337 patent/WO2019243491A1/en active Application Filing
- 2019-06-20 US US16/446,868 patent/US20200039945A1/en not_active Abandoned
- 2019-06-20 SG SG11202010450VA patent/SG11202010450VA/en unknown
- 2019-06-20 CR CR20210032A patent/CR20210032A/es unknown
- 2019-06-20 JP JP2020571368A patent/JP2021529738A/ja not_active Withdrawn
- 2019-06-20 MD MDE20210392T patent/MD3810602T2/ro unknown
- 2019-06-20 ES ES19734722T patent/ES2967983T3/es active Active
- 2019-06-20 LT LTEPPCT/EP2019/066337T patent/LT3810602T/lt unknown
- 2019-06-20 CU CU2020000096A patent/CU20200096A7/es unknown
- 2019-06-20 MA MA52948A patent/MA52948B1/fr unknown
- 2019-06-21 AR ARP190101711A patent/AR114972A1/es unknown
-
2020
- 2020-11-23 EC ECSENADI202075270A patent/ECSP20075270A/es unknown
- 2020-11-24 CO CONC2020/0014586A patent/CO2020014586A2/es unknown
- 2020-12-02 NI NI202000092A patent/NI202000092A/es unknown
- 2020-12-09 PH PH12020500673A patent/PH12020500673A1/en unknown
- 2020-12-11 CL CL2020003219A patent/CL2020003219A1/es unknown
- 2020-12-17 IL IL279554A patent/IL279554A/en unknown
- 2020-12-17 DO DO2020000249A patent/DOP2020000249A/es unknown
-
2021
- 2021-08-03 US US17/392,356 patent/US20220153710A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR114972A1 (es) | Compuestos | |
AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
AR116939A1 (es) | 2-amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8 | |
AR121044A1 (es) | Inhibidores de egfr | |
PE20191532A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR093818A1 (es) | Compuesto de 1-(bencil sustituido)piperazina sustituida | |
AR110922A1 (es) | Compuestos inhibidores del vih | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR104362A1 (es) | Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios | |
AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
AR094668A1 (es) | Amidas como moduladores de canales de sodio | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR120896A1 (es) | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz | |
AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
PE20212070A1 (es) | Moduladores de trex1 | |
RU2013116924A (ru) | N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз | |
AR098522A1 (es) | Compuesto de triazolo-piridina | |
AR119010A1 (es) | Compuestos, composiciones y métodos de uso | |
AR104880A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR107428A1 (es) | COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC | |
AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
AR106297A1 (es) | Compuestos macrocíclicos modificados como inhibidores selectivos de la quinasa cdk9 |